decongestants

出典: meddic



UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

英文文献

  • Pharmacological Evaluation of Selective α2c Adrenergic Agonists in Experimental Animal Models of Nasal Congestion.
  • Jia Y1, Mingo GG, Hunter JC, Lieber GB, Palamanda JR, Mei H, Boyce CW, Koss MC, Yu Y, Cicmil M, Hey JA, McLeod RL.Author information 1Immunology, Merck Research Laboratories, Boston, MA, USA;AbstractNasal congestion is one of the most troublesome symptoms of many upper airways diseases. We characterized the effect of selective α2c-adrenergic agonists in animal models of nasal congestion. In porcine mucosa tissue, Compound A and Compound B contracted nasal veins (EC50 = 210 and 21 nM) with only modest effects on arteries. In in vivo experiments, we examined the nasal decongestant dose response characteristics, pharmacokinetic (PK)/pharmacodynamics (PD) relationship, duration of action, potential development of tolerance and topical efficacy of α2c-adrenergic agonists. Acoustic rhinometry was used to determine nasal cavity dimensions following intranasal Compound 48/80 (1%, 75 µl). In feline experiments, Compound 48/80 decreased nasal cavity volume and minimum cross sectional areas by 77% and 40%. Compound A (0.1 - 3.0 mg/kg, p.o), Compound B (0.3 - 5.0 mg/kg, p.o.) and d-pseudoephedrine (0.3 and 1.0 mg/kg, p.o.) produced a dose-dependent decongestion. Unlike d-pseudoephedrine, Compounds A and B did not alter systolic blood pressure. The plasma exposure of Compound A to produce a robust decongestion (EC80) was 500 nM which related well to duration of action of around 4.0 hrs. No tolerance to the decongestant effect of Compound A (1.0 mg/kg, p.o.) was observed. To study the topical efficacies of Compounds A and B, the drugs were given topically 30 minutes after Compound 48/80 (a therapeutic paradigm), where both agents reversed nasal congestion. Finally, nasal decongestive activity was confirmed in the dog. We demonstrate that α2c-adrenergic agonists behave as nasal decongestants without cardiovascular actions in animal models of upper airway congestion.
  • The Journal of pharmacology and experimental therapeutics.J Pharmacol Exp Ther.2014 Feb 3. [Epub ahead of print]
  • Nasal congestion is one of the most troublesome symptoms of many upper airways diseases. We characterized the effect of selective α2c-adrenergic agonists in animal models of nasal congestion. In porcine mucosa tissue, Compound A and Compound B contracted nasal veins (EC50 = 210 and 21 nM) with only
  • PMID 24492651
  • The relationship of decongestant use and risk of decompression sickness; a case-control study of hawaiian scuba divers.
  • Smerz RW.Author information Hyperbaric Treatment Center, University of Hawai'i, John A. Burns School of Medicine, Honolulu, HI.AbstractExposure to cold, dehydration, and aging are known to contribute to the development of decompression sickness (DCS) in divers. Hypertension and nicotine usage have also been suggested as risk factors. Vasoconstriction is an underlying mechanism associated with all of these risk factors. Vasoconstriction increases the degree of bubble formation which is believed to be the cause of DCS. Formed bubbles interfere with the production of nitric oxide which modulates vascular tone resulting in vasoconstriction. Divers commonly use sympathomimetic decongestants which induce vasoconstriction to prevent barotrauma of the ears and sinuses while diving and thus theoretically may contribute to the risk for developing DCS. The purpose of this case-control study was to explore the association between decongestant usage and development of DCS in 400 divers treated/evaluated at the University of Hawai'i, John A. Burns School of Medicine between 1983 and 2010. Bivariate and logistic regression analyses were employed to evaluate differences between cases and controls. In addition to the variable of interest, other co-variables known to have significant influence in the development of DCS were appropriately controlled for during the analyses. In this study population, dehydration (OR = 2.7; 95% CI: 1.1, 7.4), repetitive diving (OR = 2.8; 95% CI: 1.8, 4.4), and violation of dive profiles (OR = 4.9; 95% CI: 3.1, 7.9) contributed independently and significantly to the development of DCS. The co-variables of cold, gender, obesity, and rapid ascents were not significant contributors to developing DCS in this study. There was a small but statistically insignificant risk associated with decongestant use (OR = 1.4; 95% CI: 0.8-2.6; P = .22). The inherent limitations associated with records-based studies may have underestimated this risk. It is important therefore that future research be undertaken to help clarify this concern.
  • Hawai'i journal of medicine & public health : a journal of Asia Pacific Medicine & Public Health.Hawaii J Med Public Health.2014 Feb;73(2):61-5.
  • Exposure to cold, dehydration, and aging are known to contribute to the development of decompression sickness (DCS) in divers. Hypertension and nicotine usage have also been suggested as risk factors. Vasoconstriction is an underlying mechanism associated with all of these risk factors. Vasoconstric
  • PMID 24567870
  • Balloon dilatation for congenital nasal piriform aperture stenosis (CNPAS): A novel conservative technique.
  • Gungor AA1, Reiersen DA2.Author information 1Department of Otolaryngology/Head & Neck Surgery, LSU-Health Shreveport, Shreveport, LA, USA.2Department of Otolaryngology/Head & Neck Surgery, LSU-Health Shreveport, Shreveport, LA, USA. Electronic address: dreier@lsuhsc.edu.AbstractCongenital nasal piriform aperture stenosis (CNPAS) is an uncommon but important cause of nasal obstruction in infants. When it is severe, nasal decongestants or temporary nasal airway devices cannot address the problem adequately. The most common surgical technique used to treat the bony piriform aperture stenosis is the sublabial approach and drill-out of the nasal aperture followed by nasal stenting. This paper describes an infant with bilateral CNPAS who underwent a single successful balloon dilatation and short-term stenting of the nasal piriform apertures without the need for additional procedures.
  • American journal of otolaryngology.Am J Otolaryngol.2014 Jan 2. pii: S0196-0709(13)00299-8. doi: 10.1016/j.amjoto.2013.12.016. [Epub ahead of print]
  • Congenital nasal piriform aperture stenosis (CNPAS) is an uncommon but important cause of nasal obstruction in infants. When it is severe, nasal decongestants or temporary nasal airway devices cannot address the problem adequately. The most common surgical technique used to treat the bony piriform a
  • PMID 24468321

和文文献

  • 一般用医薬品点鼻薬の適正使用に対する外箱情報提供とリスクマネジメントに関する日米比較
  • 大塚 邦子,安原 一,鎌江 伊三夫,大塚 誠,斉藤 洋,Jorgenson James A.
  • 医療薬学 30(7), 483-491, 2004-07-10
  • … In the present study, we investigated the differences in drug information and risk management given for OTC nasal decongestants and sprays between the United States and Japan. … We found many differences in the labeling of OTC nasal decongestants and sprays between the U.S. and Japan, which would depend on consumers' rights and product liability. …
  • NAID 110001166829
  • Comparative Study between United States and Japan Regarding Drug Information on Labeling of Over-the-counter Nasal Decongestant Drops and Sprays, and their Risk Managements
  • 大塚 邦子,安原 一,鎌江 伊三夫,大塚 誠,斉藤 洋,Jorgenson James A.
  • 医療薬学 30(7), 483-491, 2004
  • … In the present study, we investigated the differences in drug information and risk management given for OTC nasal decongestants and sprays between the United States and Japan. … In contrast, numbers were only given for 2 such centers in Japan, and they were not toll-free, deterring wide use due to the cost involved.<BR>We found many differences in the labeling of OTC nasal decongestants and sprays between the U.S. and Japan, which would depend on consumers' rights and product liability. …
  • NAID 130004118207
  • 薬物の眼粘膜吸収性に及ぼすβ-グリチルリチン酸の影響
  • 小高 明人,堀内 拓,小出 操
  • 藥學雜誌 119(7), 502-509, 1999-07-01
  • … GK2 increased the partition of cationic drugs, i.e., antihistamines(chlorpheniramine maleate (CM), diphenhydramine hydrochloride (DH)), as well as decongestants(naphazoline hydrochloride (NA), tetrahydrozoline hydrochloride (TH)). …
  • NAID 110003648757

関連リンク

Learn more about decongestants for allergy symptoms. ... By Dr. Amy Wechsler Consider it the worst type of fashion blunder: Your favorite items could be at fault for otherwise-unexplained breakouts and rashes.
Compare decongestants. View important safety information, ratings, user reviews, popularity and more... ... Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter ...

関連画像


押しても画像が表示されない場合はサーバが混雑しています。2週間ほどあけて、再度押下してください。


★リンクテーブル★
関連記事decongestant

decongestant」

  [★]

nasal decongestant

WordNet   license wordnet

「a drug that decreases pulmonary congestion」

PrepTutorEJDIC   license prepejdic

「(特に,鼻炎の)消炎剤」




★コメント★

[メモ入力エリア]
※コメント5000文字まで
ニックネーム:
コメント:




表示
個人用ツール


  meddic.jp

リンク
連絡